China accepts Innovent-HUTCHMED’s endometrial cancer therapy NDA
03 Apr 2024
Phase 2Priority ReviewNDADrug ApprovalBreakthrough Therapy
Preview
Source: Pharmaceutical Technology
The companies sought approval for sintilimab and fruquintinib to treat advanced endometrial cancer. Credit: Fancy Studio / Shutterstock.com.
The China National Medical Products Administration (NMPA) has granted priority review for Innovent Biologics and Hutchmed’s new drug application (NDA) for the combination of sintilimab and fruquintinib for advanced endometrial cancer.
The NDA seeks a new therapeutic regimen for people with proficient mismatch repair or non-microsatellite instability-high tumours who have exhausted previous systemic therapies and are not eligible for curative surgical procedures or radiation.
Sintilimab is a programmed cell death protein 1 immunoglobulin G4 monoclonal antibody, marketed in China as TYVYT (sintilimab injection). It has been developed through a collaboration between Innovent and Eli Lilly.
The application is based on the data from the FRUSICA-1 study, a Phase II multicentre, open-label trial.
The primary measure of success was the objective response rate as assessed by an independent review committee.
See Also:
FDA accepts AstraZeneca-Daiichi Sankyo’s Datopotamab deruxtecan BLA
Preview
Source: Pharmaceutical Technology
MASH revival with over $2.5bn for innovator drug partnership deals in 2024
Preview
Source: Pharmaceutical Technology
Disease control rate, duration of response, progression-free survival, overall survival and pharmacokinetic assessments were the secondary endpoints.
In July 2023, the NMPA recognised the potential of the combination therapy, granting it a breakthrough designation. This status is reserved for treatments that offer a significant advancement over existing options for serious ailments lacking effective therapies, and where clinical evidence indicates substantial benefits.
Innovent senior vice-president Dr Hui Zhou stated: “TYVYT (sintilimab injection), as a backbone therapy in immuno-oncology, in combination with an anti-angiogenetic drug, may improve the prognosis for endometrial cancer patients in China.
“We are excited about the NDA acceptance and priority review designation, which increases our potential to bring a new treatment option to endometrial cancer patients, and concurrently strengthens the leadership position of TYVYTin China.”
In August 2023, the company received approval from China NMPA for SINTBILO (tafolecimab injection) for primary hypercholesterolemia and mixed dyslipidemia.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.